Moderna Inc.

34.45
-0.26 (-0.75%)
At close: Mar 18, 2025, 11:42 AM
-0.75%
Bid 32.83
Market Cap 13.29B
Revenue (ttm) 3.24B
Net Income (ttm) -3.57B
EPS (ttm) -9.28
PE Ratio (ttm) -3.71
Forward PE -5.07
Analyst Hold
Ask 34.95
Volume 2,795,690
Avg. Volume (20D) 11,818,510
Open 34.49
Previous Close 34.71
Day's Range 33.59 - 35.00
52-Week Range 29.25 - 170.47
Beta 1.86

About MRNA

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus...

Industry Biotechnology
Sector Healthcare
IPO Date Dec 7, 2018
Employees 5,800
Stock Exchange NASDAQ
Ticker Symbol MRNA
Full Company Profile

Analyst Forecast

According to 20 analyst ratings, the average rating for MRNA stock is "Hold." The 12-month stock price forecast is $50.5, which is an increase of 46.61% from the latest price.

Stock Forecasts

Next Earnings Release

Moderna Inc. is scheduled to release its earnings on May 1, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+15.94%
Moderna shares are trading higher after CEO Stepha... Unlock content with Pro Subscription
1 week ago
+0.33%
Moderna shares are trading higher after Stephane Bancel Disclosed a share purchase.